Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

This study tests cardenilimab — a dual checkpoint inhibitor that targets both PD-1 and LAG-3 — combined with chemotherapy for locally advanced cervical cancer. The goal is to see if adding this immunotherapy to standard chemoradiation improves outcomes. **You may be eligible if...** - You are 18 or older with locally advanced cervical cancer (confirmed by biopsy) - Your cancer has not spread to distant organs - You have not received prior treatment for this cancer - Your general health and organ function are adequate (ECOG 0–1) **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have autoimmune disease requiring systemic treatment - You have had prior pelvic radiation - You are pregnant or breastfeeding - You have active hepatitis or HIV Talk to your doctor to see if this trial is right for you.